CDKL5 and craniodiaphyseal dysplasia: By tackling CDKL5 deficiency disorder (CDD) as a model of genetic brain disorder, our study provides novel evidence that a gene therapy approach based on a vector expressing a therapeutic protein fused to an Igk-TATk polypeptide provides increased protein biodistribution and therapeutic efficacy compared to the same vector devoid of the fusion peptide.